LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

430.63 -1.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

421.39

Max

437.71

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+58.17% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-661M 9.9B
Vorige openingsprijs	432.49
Vorige sluitingsprijs	430.63

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2026, 19:32 UTC

Acquisities, Fusies, Overnames

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mrt 2026, 22:26 UTC

Belangrijke Nieuwsgebeurtenissen

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mrt 2026, 22:07 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

6 mrt 2026, 21:37 UTC

Winsten

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mrt 2026, 21:25 UTC

Belangrijke Nieuwsgebeurtenissen

How The Iran War Impacts Ukraine. -- Barrons.com

6 mrt 2026, 21:17 UTC

Winsten

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mrt 2026, 20:50 UTC

Winsten

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mrt 2026, 20:46 UTC

Winsten

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mrt 2026, 20:31 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mrt 2026, 20:18 UTC

Marktinformatie

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mrt 2026, 20:12 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mrt 2026, 19:10 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mrt 2026, 18:54 UTC

Marktinformatie

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mrt 2026, 18:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mrt 2026, 18:08 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 17:49 UTC

Marktinformatie

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mrt 2026, 17:46 UTC

Belangrijke Nieuwsgebeurtenissen

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mrt 2026, 17:40 UTC

Marktinformatie

Winsten

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mrt 2026, 17:40 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 17:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mrt 2026, 17:28 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Acquisities, Fusies, Overnames

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

58.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 694.9 USD 58.17%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.